SBWire

Global Markets Direct's, 'Retinal Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Retinal Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinal Degeneration. Retinal Degeneration - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Reperfusion Injury Global Clinical Trials Review, H1, 2014" provides data on the Reperfusion Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Reperfusion Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Reperfusion Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "TWi Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the TWi Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Francisella Tularensis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections. Francisella Tularensis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Endometriosis is a gynecological disorder affecting women of childbearing age. This inflammatory condition is characterized by the growth of endometrial tissues outside of the uterus, and can cause chronic painful menstruation, painful intercourse, and infertility. For many women, endometriosis-associated pain can be so debilitating that it affects their ability to perform daily functions and significantly deters their quality of life.

Natural weight loss should be aimed for as much as possible, although it can prove to be a challenge to many people. With the help of raspberry ketone weight loss supplement , however, reducing overall body fat and consequently losing weight through natural means has become more achievable.

GlobalData's clinical trial report, "Orthostatic Hypotension Global Clinical Trials Review, H1, 2014" provides data on the Orthostatic Hypotension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Orthostatic Hypotension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Orthostatic Hypotension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Market Direct's pharmaceuticals report, "Aegis Therapeutics, LLC - Product Pipeline Review - 2013" provides data on the Aegis Therapeutics, LLC's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Jenrin Discovery, Inc. - Product Pipeline Review - 2013" provides data on the Jenrin Discovery, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

GlobalData's clinical trial report, "Ulcers Global Clinical Trials Review, H1, 2014" provides data on the Ulcers clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ulcers. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ulcers. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

OTC Medications in Japan by Mintel Global Market Navigator provides you with annual year-end market size data, most recently updated in 2013. This market covers analgesics, cough/cold/flu, gastro-intestinal, dermatological remedies and vitamins and minerals. It excludes products which require prescriptions but includes pharmacy approved. Market size comprises sales through all retail channels including direct to consumer. Market size for OTC Medications in Japan is given in JPY with a minimum of five years' historical data. Market Forecast is provided for five years. Included with this snapshot is socio-economic data for Japan. Population, Consumer Price Index (CPI), Gross Domestic Product (GDP), Exchange Rates.

Atrasentan (Microvascular Complications of Diabetes) - Forecast and Market Analysis to 2022

Global Market Direct's pharmaceuticals report, "Supratek Pharma Inc. - Product Pipeline Review - 2013" provides data on the Supratek Pharma Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Gardena, CA -- With an aim to enhance natural muscle development Muscle King Pro is now available with natural ingredients that assist individuals to experience-proven outcomes in less time. It is actually the very first accurate testosterone enhancer obtainable in the shape of the tablet. It is free of any revolting binders to hinder one’s health and 100% safe to make use of.

Global Markets Direct's, 'Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mucopolysaccharidosis II (MPS II) (Hunter Syndrome). Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

GlobalData's clinical trial report, "Hidradenitis Suppurativa Global Clinical Trials Review, H1, 2014" provides data on the Hidradenitis Suppurativa clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hidradenitis Suppurativa. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hidradenitis Suppurativa. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Sometimes, people who do not take vitamins need to understand the value of them. Sometimes, people who do take them daily need to be reinforced with the idea of how important they are. Diamond Herpanacine of PA is pleased to inform their customers on why they need vitamins in their lives. The most important thing to understand about vitamins is that they carry out the most important functions of the body.

GlobalData's clinical trial report, "Ocular Hypertension Global Clinical Trials Review, H1, 2014" provides data on the Ocular Hypertension clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ocular Hypertension. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ocular Hypertension. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, retinopathy, and neuropathy - is facing an extremely high level of unmet need across the 7MM (US, 5EU and Japan). Despite its enormous potential, the MCD market is facing the major global barrier in the sparsely populated pipeline. The diabetic retinopathy segment of the market has recently seen rapid uptake of novel anti-VEGF therapies and is experiencing a strong growth. On the other hand, the diabetic neuropathy and nephropathy segments face the barrier in and increasing number of generic competitors.

Global Market Direct's pharmaceuticals report, "Basilea Pharmaceutica AG - Product Pipeline Review - 2013" provides data on the Basilea Pharmaceutica AG's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

Global Market Direct's pharmaceuticals report, "Diakron Pharmaceuticals, Inc. - Product Pipeline Review - 2013" provides data on the Diakron Pharmaceuticals, Inc.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.